CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 46 enrolled
Drug / intervention
Bupivacaine +1 moredrug
Likely dose
Bupivacaine 20 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03757715
NCT03757715Phase 4Completed
CompareCT.gov

The Role of Regional Anesthesia to Reduce Opioid Requirements Following Functional Endoscopic Sinus Surgery (FESS)

University of Alabama at Birmingham·interventional·Posted Nov 29, 2018·Updated Aug 31, 2022

In Brief

A Phase 4 clinical trial evaluating Bupivacaine and Dexamethasone for Pain Management. Completed, enrolled 46 participants across 1 site.

Detailed Summary

Opioids are prescribed for moderate to severe pain disorders; however, there are contraindications and side effects that are common to all opioids. The investigators hypothesize using regional anesthetic during sinus surgery will reduce surgical pain, therefore decreasing the need for post-operative opioid medication. The primary of objective is to determine if a long-acting local regional anesthetic applied during a surgery will reduce post-operative oral opioid usage.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain Management
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedNov 29, 2018
Enrollment StartMay 20, 2019
Primary CompletionMar 12, 2021
Study CompletionApr 12, 2021
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.6 years ago

Interventions

Bupivacainedrug

20 mL of 1.3% bupivacaine

Dexamethasonedrug

2 mg dexamethasone